Clinical Study

Herpes Zoster Infections in SLE in a University Hospital in Saudi Arabia: Risk Factors and Outcomes

Afsar Sayeeda, Hussain Al Arfaj, Najma Khalil, and A. S. Al Arfaj

Division of Rheumatology, Department of Medicine, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Riyadh, Saudi Arabia

Correspondence should be addressed to Afsar Sayeeda, afsarsayeeda@hotmail.com

Received 26 January 2010; Revised 1 June 2010; Accepted 19 August 2010

Academic Editor: Francesco Indiveri

Copyright © 2010 Afsar Sayeeda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Patients with SLE carry an increased risk of infection that account for 11–23% of all hospitalized patients and 50% of all SLE patients develop major infections during the course of their disease. Globally Herpes Zoster has been reported as the most frequent viral infection in SLE patients. We determined the clinical spectrum, disease sequelae and the risk factors associated with the development of Herpes Zoster in patients with SLE and their outcomes. Retrospective case control study of Herpes Zoster infections was done in SLE patients between 1982 and 2006. Cases were matched 1:2 to controls for age, race, sex and duration of follow up. Clinical features of the cases from the time of lupus diagnosis to the time of Zoster were compared to their respective controls over similar time periods. Thirty two SLE cases were compared to sixty four controls. Cases were more likely to have received cyclophosphamide ($P = .0223$) and intravenous methylprednisolone pulse therapy ($P = .0026$), MMF ($P < .02$), had leucopenia ($P = .0407$) and hemolytic anemia ($P = .0344$). More cases than controls had lupus nephritis, cerebritis, thrombocytopenia but the differences did not reach statistical significance. The mean oral prednisolone dose and proportion of patients receiving immunsuppressives including pulse methylprednisolone therapy, IV Cyclophosphamide and mycophenolate was significantly higher in patients with active SLE compared to patients with SLE in remission at the time of Herpes Zoster ($P < .05$). Disseminated Zoster developed in patients with active SLE (7/9) compared to patients with SLE in remission (0/23). None of the patients had postherpetic neuralgia or bacterial super infection. Immunosuppressive medications were discontinued at the time of diagnosis of Zoster in 19 of 32 patients and all patients received antiviral medications. There were no permanent neurologic deficits or deaths. We conclude that Herpes Zoster infections occur at increased frequency among patients with SLE and carry significant morbidity. Immunosuppressive therapy and severe manifestations of lupus may be risk factors for the development of Herpes Zoster although not necessarily at the time of disease flare or immunosuppressive therapy. Our study suggests that although Herpes Zoster occurs frequently in patients with SLE, it has a relatively benign course.

1. Introduction

Herpes Zoster, a painful vesicular eruption with a dermatomal distribution, is caused by reactivation of a latent Varicella Zoster virus infection [1]. It may be complicated by bacterial superinfection and cutaneous and visceral dissemination of lesions which may be life threatening. Although it occurs most commonly in otherwise healthy elderly individuals, immunocompromised patients (i.e., those with malignancies especially lymphoproliferative diseases, organ allograft, and autoimmune diseases such as SLE) appear to be at a particular risk for both Herpes Zoster and its complications [2–8]. Herpes Zoster in these patients has a greater tendency to disseminate and to cause morbidity [9–12].

Patients with SLE may be at increased risk for Zoster infection by virtue of both the impairment in cell-mediated immunity which characterizes the disease and by treatment of severe disease with high dose corticosteroids or immunosuppressive agents. Indeed, several studies have reported an increased incidence of Herpes Zoster in patients with SLE [13–18].

There have been no studies in the Saudi population addressing the frequency or natural history of Herpes
Zoster infections in patients with SLE or the desirability of withdrawing their immunosuppressive medications and or instituting antiviral therapy.

In this paper retrospective case controlled study was used to determine its frequency, assess specific risk factors, its association with SLE disease manifestations, and their treatment, and defines prognostic indicators for serious complications of Herpes Zoster.

2. Materials and Methods

2.1. Patients. SLE patients defined by the ACR 1982 revised criteria seen at the outpatient and inpatient facilities of the university hospital that developed Herpes Zoster were considered for the period extending from 1982 to 2006. Medical records of patients with Herpes Zoster were reviewed to verify the diagnosis and to determine its treatment and outcome as well as the activity of SLE at the time of infection. Patients with Herpes Zoster but with other systemic rheumatic diseases for example, rheumatoid arthritis, dermatomyositis, overlap syndrome, and Wegener’s granulomatosis were excluded from this study.

2.2. Case Definition and Assessment of Disease. A case was defined as a patient with SLE living or deceased with a history of a characteristic vesicular rash in a dermatomal distribution. Herpes Zoster was considered to be disseminated when the dermatomal pattern was followed by progressive widespread vesicular lesions. Post herpetic neuralgia was defined as pain persisting more than 1 month after resolution of cutaneous lesions.

For the purposes of this study, we included as cases only those patients with a history of Herpes Zoster anytime after the first physician diagnosis of SLE. The diagnosis of Herpes Zoster was made from the history and the documentation of a characteristic rash with associated symptoms in a dermatomal distribution leaving little doubt as to the diagnosis. Viral isolation by culture or serology was not done for confirmation of Herpes Zoster.

A control was defined as a patient with SLE with no history of Herpes Zoster. Cases and controls were matched 1:2 by age, race, gender, and SLE disease duration (from diagnosis to the time of review), clinical manifestations, and treatment of SLE (use of high dose steroid (1 mg/kg/day) & other immunosuppressive agents) in the three months preceding and the three months following the Herpes Zoster episode. Initial disease activity was assessed by the SLE Disease Activity Index score, which is a validated measure of disease activity for patients with SLE [19].

Cumulative clinical manifestations of disease and its treatment were compared between patients with and without Herpes Zoster to determine its risk factors. Events were analyzed up to and including the time of the first Herpes Zoster episode in the infected group and to date of the last followup in the uninfected group, to compare disease features during the period when the patients were at risk of first Zoster episode.

Risk factors were defined by the ever use and dose of prednisolone, use of an immunosuppressive medication, lupus nephritis. The presence of these potential risk factors in cases was determined from the time of SLE diagnosis to the time of Herpes Zoster infection and in controls over similar time periods.

2.3. Statistical Analysis. Data were analyzed by SPSS version 12 and the results are presented as percentages and means. Comparison of variables was carried out using chi-square test or Fisher’s exact test when appropriate. Statistical significance was defined as $P < .05$.

3. Results

A total of 32 cases of Herpes Zoster infection were identified among 624 SLE patients which gives a prevalence of 5.1% of Herpes Zoster infections in SLE. The demographic and clinical features as well as therapy in 32 Herpes Zoster SLE patients were compared with 64 non-Herpes Zoster SLE patients (patients: controls in ratio of 1:2) as shown in Table 1.

Table 1 shows that 30 (93.8%) of Herpes Zoster patients were female and 2 (6.3%) were male. Their mean age was 31.4 ± 11.4 years (range 11–60 years) and the mean duration of SLE was 8.6 ± 6.0 years (range 2–22 years). Of them, 30 were Arabs (Saudi and non-Saudi), 1 was Indian, and 1 was Pakistani. The disease was more active in our cases with a mean SLEDAI = 20.7 ± 9.8 (range 2–36) when compared to controls mean SLEDAI = 12.6 ± 5.2 (range 2–29) $P < .0001$.

Regarding the disease manifestations, it was found that nephritis occurred in 18 (56.3%), cerebritis in 2 (6.3%), serositis in 9 (28.1%), leucopenia in 17 (53.1%), thrombocytopenia in 8 (25.0%), and hemolytic anemia in 11 (34.4%) patients. All the 32 patients (100%) received oral prednisolone (PSL), 14 (43.8%) received intravenous cyclophosphamide (Cyclo IV), 16 (50.0%) pulse methyl-prednisolone (MPSL), 14 (43.8%) azathioprine (AZA), and 6 (18.8%) mycophenolate mofetil (MMF). The mean daily dose of oral PSL was 21.9 ± 27.7 mg (range 5–100 mg). Cyclo IV was given in 12 doses as 10 mg/Kg in 18 months. The mean daily dose of AZA was 125.0 ± 25.0 mg (range 100–150 mg) and of MMF was 1.1 ± 1.1 gm (range 0.5–3 gm).

The female to male ratio and racial background were similar in the two groups. Herpes Zoster SLE cases were significantly more likely to have had leucopenia ($P = .04$) and hemolytic anemia ($P = .03$) compared to non-Herpes Zoster SLE controls. Although the other serious manifestations including nephritis, cerebritis, serositis, and thrombocytopenia were more frequent in cases compared to controls, the differences did not reach statistical significance ($P > .05$). Immunosuppressives, in particular Cyclophosphamide IV ($P = .0223$) and pulse methylprednisolone (MPSL) ($P = .0026$), were more frequently prescribed to Herpes Zoster SLE patients compared to non-Herpes Zoster SLE patients.

Herpes Zoster lesions were disseminated in 7 (21.9%) of the 32 patients and localized in 25 (78.1%). Treatment of Herpes Zoster infection comprised of antiviral therapy.
Table 1: Comparison of demographic and clinical features in SLE Zoster and SLE Non-Zoster patients.

| Characteristics | Cases               | Controls               | P value |
|-----------------|---------------------|------------------------|---------|
|                 | SLE with Zoster     | SLE without Zoster     |         |
|                 | (n = 32) N (%)      | (n = 64) N (%)         |         |
| Sex             |                     |                        |         |
| Male            | 2 (6.3)             | 4 (6.3)                | .7656   |
| Female          | 30 (93.8)           | 60 (93.8)              |         |
| Race            |                     |                        | .7656   |
| Arabs           | 30 (93.8)           | 61 (95.3)              |         |
| Non Arabs       | 2 (6.3)             | 3 (4.7)                |         |
| Nephritis       | 18 (56.3)           | 28 (43.8)              | .2474   |
| Cerebritis      | 2 (6.3)             | 2 (3.1)                | .5075   |
| Serositis       | 9 (28.1)            | 13 (20.3)              | .4089   |
| Leucopenia      | 17 (53.1)           | 20 (31.2)              | .0407*  |
| Thrombocytopenia| 8 (25.0)            | 11 (17.2)              | .3879   |
| Hemolytic anemia| 11 (34.4)           | 9 (14.1)               | .0344*  |
| Cyclo IV        | 14 (43.8)           | 13 (20.3)              | .0223*  |
| MPSL            | 16 (50.0)           | 12 (18.8)              | .0026*  |
| Azathioprine    | 14 (43.8)           | 20 (31.2)              | .2336   |
| MMF             | 6 (18.8)            | 6 (9.4)                | .2318   |

* significant (P < .05), Cyclo IV: intravenous cyclophosphamide, MPSL:methyl prednisolone, MMF: mycophenolate mofetil.

acyclovir that was administered to 19 (59.5%) patients in
oral form and to 13 (40.5%) patients intravenously. SLE was
active at the time of Herpes Zoster infection in 9 (28.1%)
and in remission in 23 (71.9%) patients. The duration
of SLE remission ranged from 2 months to 4 years. SLE
did not flare up in response to Herpes Zoster infection.
Immunosuppressives were continued in 13 (40.6%) and
discontinued in 19 (59.4%) patients.

Results of SLE treatment regimens at the time of Zoster
in relation to disease activity are presented in Table 2. The
mean oral PSL dose and proportion of patients receiving
immunosuppressives including pulse MPSL, cyclo IV, and
MMF was significantly higher in patients with active SLE
compared to patients with SLE in remission at the time of
Zoster (P < .05).

Disseminated Zoster developed in patients with active
SLE (7/9) compared to patients with SLE in remission (0/23).
This explains the results in Table 3 that those who developed
disseminated Herpes Zoster had received significantly more
immunosuppressives than those who developed localized
Herpes Zoster (P < .05).

4. Discussion

Herpes Zoster reactivation of the Varicella Zoster virus
(VZV) occurs in 10%–20% of population over a lifetime
[2, 20]. The annual incidence of Herpes Zoster is less than
0.5% in the general population. Herpes Zoster occurs in
patients with SLE much more commonly than generally
expected [14].

Immunological studies on patients with SLE showed
that there are basic defects present in the disease itself (i.e.,
impaired cell-mediated immunity, defective delayed hyper-
sensitivity reaction and a hyperactive humoral immunity).
The effects of medication (high dose corticosteroids and
immunosuppressive agents or both) used to treat severe
disease may further lead to a reduction in the host resistance
to infections [21–25].

The predisposing risk factors and the nature of compli-
cations in SLE patients vary significantly among different
ethnic and geographical groups. Japanese patients with SLE
seem to be much more susceptible to Herpes Zoster with
an incidence of 43% [13, 14], the reported prevalence in
different series varying from 13.5% to 46.6% of adult SLE
patients. This is much higher than what we found in our
population of patients with SLE, the prevalence rate for
Herpes Zoster being 6% and by Al-Rayes et al. 5% [26].

Patients who had Herpes Zoster also experienced more
episodes of major infections during their disease course [27].
This could be due to disease activity, immunosuppressive
therapy and host genetic factors that determine the general
susceptibility to both infections and SLE. T cell function
plays an important role in maintaining VZV latency in the
host. In this study, two thirds of the patients had heightened
lupus activity within the 6-month period before Herpes
Zoster either because of disease onset or flare up.

Herpes Zoster lesions were localized in 25% of our
patients. The incidence of patients with dissemination in
our study was much higher (21.9%) compared to the other
studies which ranged from 2%–11% [28, 29]. The reason
may be that this is more common among patients receiving
high-dose steroids and immunosuppressives [29] or due to
a delay in instituting antiviral therapy. The mean dose of
oral prednisolone in our SLE cases at the time of Herpes
Zoster was 80 mg compared to 12 mg in controls. A reduction
in the dose of steroids should be strongly considered in
patients receiving high-dose prednisolone at the onset of Zoster episode.

All our Herpes Zoster patients had uneventful recovery. Two patients had multiple episodes (2 each), and three of them had Herpes Zoster ophthalmicus, none of them had clinically apparent CNS or visceral involvement or other complications such as permanent motor deficits, pneumonia, cutaneous scarring, regardless of treatment, or continuation of immunosuppressive medications. None of our patients had post herpetic neuralgia. No patient had bacterial superinfection and there were no deaths. Herpes Zoster in our SLE patients was relatively mild and is similar to that reported by Moutsopoulos et al. in his series [15].

All our patients received antiviral therapy either in the oral or IV form. Immunosuppressives were discontinued in 59% of our patients but given the duration of action of immunosuppressant agents, altering their regimen will probably be of no benefit [28].

In our series and in the series of Khal et al., patients who developed Zoster were more likely to have experienced serious manifestation of SLE, including nephritis, hemolysis, and thrombocytopenia and to have required treatment with cyclophosphamide. In addition, our patients had received intravenous methylprednisolone therapy. The retrospective nature of the study may have led us to miss episodes of Zoster among patients with less serious SLE who might either have had less frequent routine visits or have been less likely to seek medical attention for their Zoster. Moreover, two thirds of our patients had no major SLE organ involvement and were receiving neither high dose steroids nor immunosuppressive therapy in the three months prior to and including the Zoster episode but still sought medical attention. Many of the Zoster reactivations in both these series occurred when SLE was inactive.

Similar results were shown by Manzi et al. who also noted that the patients who developed Zoster had more severe SLE [16]. They also found immunosuppressive therapy to be a risk factor for the development of Herpes Zoster infections in these patients. Whether immunosuppressive therapy acts as a marker for lupus activity which may be an independent risk factor for Herpes Zoster could not be ascertained from their study. Both bacterial and viral infections have been associated with overall disease activity in hospitalized patients with SLE, independent of immunosuppressive therapy [30].

### 5. Conclusion

We conclude that Herpes Zoster infections occur at increased frequency among patients with SLE and have a relatively benign course. Herpes Zoster infections in patients with lupus are not necessarily associated with excessive morbidity; discontinuing needed immunosuppressive therapy in patients with SLE may be unnecessary in the setting of Zoster infection. Herpes Zoster SLE cases were significantly more likely to have had serious disease manifestations. The mean oral PSL dose and proportion of patients receiving immunosuppressive including pulse PSL, cyclo IV, and mycophenolate was significantly higher in patients with active SLE compared to patients with SLE in remission at the time of Zoster (P < .05). Disseminated Zoster developed in patients with active SLE (7/9) compared to patients with SLE in remission (0/23).

Observations by various other authors along with our own suggest that the primary risk for Zoster in patients with SLE is the basic immunologic imbalance intrinsic to lupus, rather than some distinctive immunologic abnormality associated with disease flares or their treatment. Aggressive treatment regimens for lupus, in contrast, are associated with the risk for potentially serious complications of Zoster and patients receiving such regimens should be managed with increased clinical vigilance.

### Table 2: SLE treatment at the time of Zoster infection in relation to SLE activity.

| SLE treatment | Active SLE (n = 9) N (%) | SLE in remission (n = 23) N (%) | P value |
|---------------|-------------------------|--------------------------------|---------|
| MPSL          | 3 (88.9)                | 8 (34.7)                       | .0007*  |
| Cyclo IV      | 7 (77.8)                | 7 (30.4)                       | .0086*  |
| AZA           | 6 (66.7)                | 8 (34.8)                       | .0964*  |
| MMF           | 6 (66.7)                | 0 (0.0)                        | .0002*  |

*significant (P < .05), Cylo IV: intravenous cyclophosphamide, MPSL:methyl prednisolone, AZA: azathioprine, MMF: mycophenolate, mofetil Oral PSL: (Oral prednisolone).

(All patients (100%) received oral prednisolone. The mean dose in active SLE cases was 80 ± 3 mg and in patients with SLE in remission was 12.2 ± 1 mg).

### Table 3: Disseminated/Localized Zoster in relation to SLE treatment.

| SLE Therapy | Disseminated (n = 7) | Localized (n = 25) | P value |
|-------------|----------------------|--------------------|---------|
|             | N (%)                | N (%)              |         |
| MPSL        | 6 (85.7)             | 10 (40.0)          | .0094*  |
| Cyclo IV    | 6 (85.7)             | 8 (32.0)           | .0024*  |
| AZA         | 5 (71.4)             | 9 (36.0)           | .0808*  |
| MMF         | 6 (85.7)             | 0.0 (0.0)          | .0000*  |

*significant (P < .05), Cylo IV: intravenous cyclophosphamide, MPSL:methyl prednisolone, AZA: azathioprine, MMF: mycophenolate, mofetil Oral PSL: (Oral prednisolone).
References

[1] R. Mahalingam, M. Wellish, W. Wolf et al., “Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia,” New England Journal of Medicine, vol. 323, no. 10, pp. 627–631, 1990.

[2] S. E. Straus, J. M. Ostrove, G. Inchauspe et al., “Varicella-zoster virus infections: biology, natural history, treatment, and prevention,” Annals of Internal Medicine, vol. 108, no. 2, pp. 221–237, 1988.

[3] A. E. Miller, “Selective decline in cellular immune response to varicella-zoster in the elderly,” Neurology, vol. 30, no. 6, pp. 582–587, 1980.

[4] A. A. Gershon and S. P. Steinberg, “Cellular and humoral immune responses to varicella-zoster virus in immunocompromised patients during and after varicella-zoster infections,” Infection and Immunity, vol. 25, no. 1, pp. 170–174, 1979.

[5] T. H. Weller, “Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. (Second of two parts),” New England Journal of Medicine, vol. 309, no. 23, pp. 1434–1440, 1983.

[6] M. H. Mazur and R. Dolin, “Herpes zoster at the NIH: a 20 year experience,” American Journal of Medicine, vol. 65, no. 5, pp. 738–744, 1978.

[7] D. R. Goffinet, E. J. Glatstein, and T. C. Merigan, “Herpes zoster-varicella infections and lymphoma,” Annals of Internal Medicine, vol. 76, no. 2, pp. 235–240, 1972.

[8] J. J. Rusthoven, P. Ahlgren, T. Elhakim et al., “Varicella-zoster infection in adult cancer patients. A population study,” Archives of Internal Medicine, vol. 148, no. 7, pp. 1561–1566, 1988.

[9] J. G. Gallagher and T. C. Merigan, “Prolonged herpes-zoster infection associated with immunosuppressive therapy,” Annals of Internal Medicine, vol. 91, no. 6, pp. 842–846, 1979.

[10] K. Junker, C. Avnstorp, C. M. Nielsen, and N. E. Hansen, “Reinfection with varicella-zoster virus in immunocompromised patients,” Current Problems in Dermatology, vol. 18, pp. 152–157, 1989.

[11] G. Schuler and N. Sepp, “Herpesvirus infections in the immunocompromised host. Clinical spectrum, diagnosis, management and prophylaxis,” Current Problems in Dermatology, vol. 18, pp. 137–151, 1989.

[12] R. Dolin, R. C. Reichman, M. H. Mazur, and R. J. Whitney, “Herpes zoster-varicella infections in immunosuppressed patients,” Annals of Internal Medicine, vol. 89, no. 3, pp. 375–388, 1978.

[13] T. Hamaguchi, Y. Kotani, S. Imanaka, S. Morito, and Y. Kawamura, “Lupus erythematosus and herpes zoster,” Mie Medical Journal, vol. 19, no. 3, pp. 189–192, 1970.

[14] K. Nagasawa, Y. Yamauchi, Y. Tada, T. Kusaba, Y. Niho, and H. Yoshikawa, “High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis,” Annals of the Rheumatic Diseases, vol. 49, no. 8, pp. 630–633, 1990.

[15] H. M. Moutsopoulos, J. D. Gallagher, J. L. Decker, and A. D. Steinberg, “Herpes zoster in patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 21, no. 7, pp. 798–802, 1978.

[16] S. Manzi, J. Kutzker, R. Ramsey-goldman, L. Kuller, and T. Medsger, “The epidemiology of herpes zoster in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 35, p. S240, 1992.

[17] E. L. Dubois and D. L. Tuffanelli, “Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases,” Journal of the American Medical Association, vol. 190, pp. 104–111, 1964.

[18] Y. Ishigatsubo, K. Tani, H. Sakamoto, et al., “Herpes zoster in patients with systemic lupus erythematosus,” Japanese Journal of Infection Diseases, vol. 56, pp. 272–277, 1982.

[19] C. Bombardier, D. D. Gladman, M. B. Urowitz, D. Caron, and C. H. Chang, “Derivation of the SLEDAI: a disease activity index for lupus patients the Committee on Prognosis Studies in SLE,” Arthritis and Rheumatism, vol. 35, pp. 630–640, 1992.

[20] M. W. Ragozzino, L. J. Melton III, and L. T. Kurland, “Population-based study of herpes zoster and its sequelae,” Medicine, vol. 61, no. 5, pp. 310–316, 1982.

[21] A. N. Theofilopoulos, Basic and Clinical Immunology, Appleton and Lang, Norwalk, Conn, USA, 6th edition, 1978.

[22] B. H. Hahn, M. K. Bagby, and C. K. Osterland, “Abnormalities of delayed hypersensitivity in systemic lupus erythematosus,” American Journal of Medicine, vol. 55, no. 1, pp. 25–31, 1973.

[23] A. B. Gottlieb, R. G. Lahita, N. Chiorazzi, and H. G. Kunkel, “Immune function in systemic lupus erythematosus. Impairment of in vitro T-cell proliferation and in vivo antibody response to exogenous antigen,” Journal of Clinical Investigation, vol. 63, no. 5, pp. 885–892, 1979.

[24] C. J. Rosenthal and E. C. Franklin, “Depression of cellular mediated immunity in systemic lupus erythematosus. Relation to disease activity,” Arthritis and Rheumatism, vol. 18, no. 3, pp. 207–217, 1975.

[25] E. R. Hurd, W. Dowdle, H. Casey, and M. Ziff, “Virus antibody levels in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 13, no. 3, pp. 267–274, 1972.

[26] H. Al-Rays, R. Al-Swaim, M. Arfin, S. Sobki, S. Rizvi, and M. Tariq, “Systemic lupus erythematosus and infections: a retrospective study in Saudis,” Lupus, vol. 16, no. 9, pp. 755–763, 2007.

[27] P. P. W. Lee, T.-L. Lee, M. Hok-Kung Ho, W. H. S. Wong, and Y.-L. Lau, “Herpes zoster in juvenile-onset systemic lupus erythematosus: incidence, clinical characteristics and risk factors,” Pediatric Infectious Disease Journal, vol. 25, no. 8, pp. 728–732, 2006.

[28] S. Manzi, L. H. Kuller, J. Kutzker et al., “Herpes zoster in systemic lupus erythematosus,” Journal of Rheumatology, vol. 22, no. 7, pp. 1254–1258, 1995.

[29] L. E. Kahl, “Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome,” Journal of Rheumatology, vol. 21, no. 1, pp. 84–86, 1994.

[30] K. N. W. Duffy, C. M. Duffy, and D. D. Gladman, “Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients,” Journal of Rheumatology, vol. 18, no. 8, pp. 1180–1184, 1991.